First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

This is a single arm, multicenter study which will recruit about 30 patients in China. The study is designed to evaluate the efficacy and safety of furmonertinib in the first-line treatment of patients with EGFR G719X/S768I/L861Q mutations in advanced NSCLC. Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.